Gilead EVP receives 470-share stock award vesting

Gilead Sciences executive reports stock award vesting.

Rhea-AI Filing Summary

Gilead Sciences executive reports stock award vesting. EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M acquired 470 shares of Gilead common stock on the reported date at a stated price of $0.00 per share, increasing directly held common stock to 4,414 shares.

The shares relate to specific tranches of performance share awards originally granted on March 10, 2025. These tranches were subject to both performance-vesting and service-vesting conditions, with the performance goals certified as attained by the Compensation and Talent Committee on the reported vesting date.

Insider Trade Summary

Grant/Award: 470 shares

Grant/Award 1 txn

Insider Cain Wettan Keeley M

Role EVP Gen Counsel, Legal & Comp

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	470	$0.00	$0.00

Holdings After Transaction: Common Stock — 4,414 shares (Direct)

Footnotes (1)

1. F1. Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2025. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Gilead Sciences (GILD) report for Cain Wettan Keeley M?

Gilead Sciences reported that executive Cain Wettan Keeley M acquired 470 shares of common stock through a stock award vesting. This was recorded as a grant or other acquisition, not an open-market purchase, and reflects performance-based compensation vesting.

Was the Gilead Sciences (GILD) insider transaction an open-market stock purchase?

No, the transaction was not an open-market purchase. The 470 Gilead shares were acquired at a stated price of $0.00 per share as part of performance share awards that vested, reflecting compensation rather than a discretionary market buy.

How many Gilead (GILD) shares does Cain Wettan Keeley M hold after this Form 4?

After this transaction, Cain Wettan Keeley M directly holds 4,414 shares of Gilead common stock. The increase comes from the vesting of 470 shares tied to performance share awards, following certification of performance goal attainment by the board committee.

What triggered the vesting of performance share awards for Gilead executive Cain Wettan Keeley M?

The vesting was triggered when the Compensation and Talent Committee certified that performance goals were attained. Specific tranches of performance share awards granted on March 10, 2025 then satisfied both performance-vesting and service-vesting requirements, resulting in 470 common shares being credited.

How is the Gilead (GILD) Form 4 transaction coded and what does it mean?

The transaction is coded “A,” indicating a grant, award, or other acquisition of non-derivative securities. For this filing, it represents 470 Gilead common shares acquired at a stated price of $0.00 per share through vesting of performance-based stock awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 04:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cain Wettan Keeley M

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Gen Counsel, Legal & Comp

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		470	A(1)	$0	4,414	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2025. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Keeley M. Cain Wettan	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.